The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies
Ciro Rinaldi, MD, PhD, United Lincolnshire Teaching Hospital and University of Lincoln, Lincoln, UK, shares insights into his work investigating alterations in calreticulin and CD47 expression dynamics in myeloid malignancies, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), highlighting that CD47 overexpression is associated with resistance to certain treatments. Prof. Rinaldi notes that his team is also investigating the role of macrophage polarization in CD47 and calreticulin deregulation and exploring the potential of macrophage checkpoint inhibitors as a new therapeutic approach. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
